证券代码：001328 证券简称：登康口腔 公告编号：2025-014 重庆登康口腔护理用品股份有限公司 关于2024年度利润分配方案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 一、审议程序 重庆登康口腔护理用品股份有限公司（以下简称"公司"）于2025年4月18日召开 了第七届董事会第二十一次会议及第七届监事会第十七次会议，分别全票审议通过了 《关于公司2024年度利润分配方案的议案》，该议案尚需提交公司2024年年度股东会 审议。 二、利润分配方案的基本情况 1.分配基准：2024年度。 2.经信永中和会计师事务所（特殊普通合伙）审计，2024年度公司合并报表净利 润为人民币161,179,433.51元，母公司净利润为人民币160,419,493.48元。根据《公司 法》和《重庆登康口腔护理用品股份有限公司章程》（以下简称"《公司章程》"） 的有关规定，因本年度提取7,395,381.09元法定盈余公积后，公司累计提取的法定盈余 公积已达到注册资本的50%，故本年度不再计提其余的法定盈余公积。截至2024年12 月31日，公司合并报表期末可供 ...

Financial Performance - The company's operating revenue for 2024 reached ¥1,560,070,850.25, representing a 13.40% increase compared to ¥1,375,779,690.67 in 2023[17]. - The net profit attributable to shareholders for 2024 was ¥161,179,433.51, up 14.07% from ¥141,296,591.71 in 2023[17]. - The net profit after deducting non-recurring gains and losses was ¥135,130,148.16, reflecting a significant increase of 27.07% from ¥106,343,012.57 in 2023[17]. - The net cash flow from operating activities improved to ¥181,068,159.60, a 20.09% increase from ¥150,780,838.32 in the previous year[17]. - Basic earnings per share for 2024 were ¥0.94, a 6.82% increase compared to ¥0.88 in 2023[17]. - Total assets at the end of 2024 amounted to ¥1,965,564,123.58, marking a 5.18% increase from ¥1,868,846,827.00 in 2023[17]. - The net assets attributable to shareholders increased to ¥1,454,473,374.53, a growth of 3.50% from ¥1,405,266,911.02 in 2023[17]. - The weighted average return on net assets for 2024 was 11.27%, a slight decrease of 0.70% from 11.97% in 2023[17]. Market Trends - The oral care industry in China is experiencing a structural recovery, driven by online sales channels, with the toothpaste market expanding significantly[25][26]. - The market for high-end and professional oral care products is growing, with increased consumer awareness leading to a shift from basic cleaning to health care[27]. - The demand for oral care products is becoming more segmented, with a focus on tailored solutions for children and the elderly, reflecting changing demographics[28]. - The competitive landscape is intensifying due to channel fragmentation, with a rise in e-commerce and new retail formats, necessitating a comprehensive operational strategy[29]. - The top ten toothpaste manufacturers hold approximately 80% of the market share, with local brands showing stronger resilience compared to foreign competitors[30]. Product Development and Innovation - The company is focused on expanding its market presence and developing new products and technologies to drive future growth[5]. - The company has expanded its product offerings into electric oral care products, achieving a 35.45% year-on-year revenue growth in oral medical and beauty care products in 2024[37]. - The company is focusing on high-efficacy, high-premium toothpaste products, with an increasing consumer demand for medical-grade efficacy in oral care[1]. - The company is committed to providing comprehensive oral health solutions, positioning itself as a leading professional oral care enterprise in China[33]. - The company has developed a range of children's toothbrushes tailored to different age groups, including three main series: "Percent Care," "Safe Care," and "Growth Care"[40]. - The company has introduced a series of mouthwashes with different functions and flavors to meet diverse consumer needs[42]. - The company has developed a 7-day specialized repair toothpaste using bioactive glass ceramic materials, reinforcing its technological leadership in the industry[46]. Sales and Marketing Strategy - The company has established a marketing network covering various channels, including distributors, supermarkets, and e-commerce platforms like Tmall and Douyin, enhancing brand awareness and market penetration[50]. - The company employs a multi-brand strategy, including brands like "Dengkang" and "Beilele," to cater to diverse consumer needs across different age groups[52]. - The company emphasizes digital transformation and innovative marketing strategies, winning multiple awards for its brand campaigns from 2019 to 2024[54]. - Brand exposure reached a record high of 13.2 billion times, driven by integrated marketing campaigns and collaborations, significantly enhancing brand visibility and professional value[72]. Research and Development - The R&D strategy focuses on a "marketing + R&D" dual-driven approach, ensuring alignment with market demands and fostering innovation[44]. - The company collaborates with various universities and research institutions to enhance its innovation capabilities, particularly in oral health[46]. - The R&D team includes over 20 PhD professionals and is equipped with advanced research instruments, enabling effective responses to differentiated oral health needs[59]. - The company has established 18 collaborative projects with academic and research institutions, focusing on oral diseases in special populations such as children and the elderly[62]. Corporate Governance and Compliance - The company has established a comprehensive governance structure, including a shareholder meeting, board of directors, supervisory board, and senior management, ensuring clear responsibilities and effective checks and balances[129]. - The company operates independently from its controlling shareholders in terms of assets, personnel, finance, organization, and business, maintaining a complete and independent business system[131]. - The company has an independent financial department and accounting system, allowing for independent financial decision-making and compliance with tax regulations[134]. - The company has committed to ensuring that its public offering does not involve any fraudulent issuance[193]. Sustainability and Social Responsibility - The company is committed to sustainability initiatives, with plans to reduce carbon emissions by 20% by 2025[1]. - The company is committed to social responsibility, focusing on oral health education and supporting rural revitalization initiatives[179]. - The company has taken measures to reduce carbon emissions, with details available in the ESG report[178]. Future Outlook - The company plans to enhance its market share in oral care products such as toothpaste, toothbrushes, and mouthwash through innovation and marketing strategies[109]. - By 2025, the company will focus on upgrading its oral health strategy and developing a comprehensive oral health ecosystem[110]. - The company aims to strengthen its market position by diversifying its product offerings in oral care and dental medical devices[86].

Financial Performance - The company's revenue for Q1 2025 reached ¥430,348,401, representing a 19.36% increase compared to ¥360,558,430 in the same period last year[7] - Net profit attributable to shareholders was ¥43,152,551.59, up 15.64% from ¥37,316,068.68 year-on-year[7] - The net profit after deducting non-recurring gains and losses increased by 27.25%, amounting to ¥35,815,394.04 compared to ¥28,145,141.34 in the previous year[7] - Basic and diluted earnings per share rose to ¥0.25, reflecting a 13.64% increase from ¥0.22[7] - Total operating revenue for the current period reached ¥430,348,401, an increase of 19.4% compared to ¥360,558,430 in the previous period[17] - Net profit for the current period was ¥43,152,551.59, representing a growth of 15.4% from ¥37,316,068.68 in the previous period[17] - Earnings per share (EPS) increased to ¥0.25, compared to ¥0.22 in the prior period[17] Cash Flow and Investments - The net cash flow from operating activities was ¥65,146,373.34, a significant increase of 35.39% from ¥48,116,575.01 in the same quarter last year[7] - Operating cash flow for the current period was ¥65,146,373.34, an increase of 35.4% compared to ¥48,116,575.01 in the previous period[18] - Total cash inflow from investment activities was ¥461,336,624.62, up from ¥225,267,602.73, representing a 105.5% increase[18] - Cash outflow from investment activities totaled ¥742,143,151.78, compared to ¥289,430,375.93 in the previous period, indicating a significant increase of 156.5%[18] - The net cash flow from investment activities was -¥280,806,527.16, worsening from -¥64,162,773.20 in the previous period[18] - Cash received from the recovery of investments was ¥455,000,000.00, significantly higher than ¥170,000,000.00 in the previous period[18] - Cash paid for the purchase of fixed assets was ¥20,143,151.78, compared to ¥9,430,375.93 in the previous period, reflecting an increase of 113.5%[18] - Cash paid for investments was ¥572,000,000.00, up from ¥280,000,000.00, marking a 104.3% increase[18] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,036,758,576.49, a 3.62% increase from ¥1,965,564,123.58 at the end of the previous year[7] - Total liabilities rose to ¥539,132,650.38, up from ¥511,090,749.05 in the previous period, indicating a growth of 5.5%[16] - Current liabilities totaled ¥482,739,369.83, an increase of 7.3% from ¥450,815,229.09 in the previous period[16] - Non-current liabilities decreased slightly to ¥56,393,280.55 from ¥60,275,519.96, a decline of 6.3%[16] - Total equity attributable to shareholders increased to ¥1,497,625,926.11, up from ¥1,454,473,374.53, reflecting a growth of 3.0%[16] Shareholder Information - The company reported a total of 8,312 common stock shareholders at the end of the reporting period[12] - The largest shareholder, Chongqing Light Textile Holdings Group, holds 59.83% of shares, totaling 103,012,300 shares[12] - The company has a significant presence of institutional investors, with the top 10 shareholders holding a combined 73.2% of shares[12] Strategic Initiatives - The company is exploring market expansion strategies and new product development initiatives[12] - Future performance guidance indicates a focus on enhancing operational efficiency and increasing market share[12] Tax and Other Expenses - The company reported a 66.20% increase in taxes and surcharges, totaling ¥2,944,437.98, driven by higher sales revenue[10] - Total operating costs amounted to ¥384,076,059, up 17.9% from ¥325,399,141 in the prior period[17]

登康口腔（001328）公告，2025年第一季度营业收入4.3亿元，同比增长19.36%。净利润4315.26万元， 同比增长15.64%。 ...

内部控制审计报告 XYZH/2025CDAA7B0164 重庆登康口腔护理用品股份有限公司 2024 年 12 月 31 日 内部控制审计报告 | 索引 | 页码 | | --- | --- | | 内部控制审计报告 | 1-2 | 一、 企业对内部控制的责任 按照《企业内部控制基本规范》 、《企业内部控制应用指引》 、《企业内部控制评 价指引》的规定，建立健全和有效实施内部控制，并评价其有效性是登康口腔公司董事 会的责任。 二、 注册会计师的责任 我们的责任是在实施审计工作的基础上，对财务报告内部控制的有效性发表审计意 见，并对注意到的非财务报告内部控制的重大缺陷进行披露。 三、 内部控制的固有局限性 内部控制具有固有局限性，存在不能防止和发现错报的可能性。此外，由于情况的 变化可能导致内部控制变得不恰当，或对控制政策和程序遵循的程度降低，根据内部控 制审计结果推测未来内部控制的有效性具有一定风险。 1 重庆登康口腔护理用品股份有限公司 重庆登康口腔护理用品股份有限公司全体股东： 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求，我们审计 了重庆登康口腔护理用品股份有限公司（以下简称登康口腔公 ...

中信建投证券股份有限公司 关于重庆登康口腔护理用品股份有限公司 2024 年度募集资金存放与使用情况的专项核查报告 中信建投证券股份有限公司（以下简称"中信建投证券"或"保荐人"）作 为重庆登康口腔护理用品股份有限公司（以下简称"登康口腔"或"公司"）首 次公开发行股票并在主板上市的保荐人，根据《证券发行上市保荐业务管理办法》 《深圳证券交易所股票上市规则》《上市公司监管指引第 2 号——上市公司募集 资金管理和使用的监管要求》《深圳证券交易所上市公司自律监管指引第 1 号— —主板上市公司规范运作》等相关规定，对公司 2024 年度募集资金存放与使用 情况进行了核查，核查情况及核查意见如下： 1 | 项目 | | 序号 | 金额（万元） | | --- | --- | --- | --- | | 募集资金净额 | | A | 82,581.45 | | 截至 2023 年累计发生额 | 项目投入 | B1 | 26,291.47 | | | 存款利息收入 | B2 | 891.51 | | | 现金管理收益 | B3 | 41.61 | | | 银行手续费支出 | B4 | 0.53 | | 年末应结余募集 ...

关于重庆登康口腔护理用品股份有限公司 2024 年度日常关联交易补充确认及增加 2025 年度日常关联 交易预计的核查意见 中信建投证券股份有限公司（以下简称"中信建投证券"或"保荐人"）作 为重庆登康口腔护理用品股份有限公司（以下简称"登康口腔"或"公司"）首 次公开发行股票并在主板上市的保荐人，根据《证券发行上市保荐业务管理办法》 《深圳证券交易所股票上市规则》《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》等相关规定，对公司 2024 年度日常关联交易补 充确认及增加 2025 年度日常关联交易预计情况进行了审慎核查，核查具体情况 如下： 公司于 2025 年 1 月 22 日召开的第七届董事会第二十次会议审议通过了《关 于 2024 年度日常关联交易确认及 2025 年度日常关联交易预计的议案》，具体内 容详见公司于 2025 年 1 月 23 日在《中国证券报》《上海证券报》《证券日报》 《证券时报》《经济参考报》和巨潮资讯网（www.cninfo.com.cn）披露的《关于 2024 年度日常关联交易确认及 2025 年度日常关联交易预计的公告》（公告编号： 2025-00 ...

中信建投证券股份有限公司 关于重庆登康口腔护理用品股份有限公司 2024 年度内部控制评价报告的核查意见 中信建投证券股份有限公司（以下简称"中信建投证券"或"保荐人"）作 为重庆登康口腔护理用品股份有限公司（以下简称"登康口腔"或"公司"）首 次公开发行股票并在主板上市的保荐人，根据《证券发行上市保荐业务管理办法》 《深圳证券交易所股票上市规则》《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》等相关规定，对《重庆登康口腔护理用品股份有 限公司 2024 年度内部控制评价报告》进行了审慎核查，核查情况及核查意见如 下： 一、内部控制评价工作情况 （一）内部控制评价范围 3、重点关注的高风险领域主要包括：资金营运管理、投资管理、采购与应 付账款管理、存货管理、销售与应收账款管理、生产管理等。 上述纳入评价范围的单位、业务和事项以及高风险领域涵盖了公司经营管理 1 的主要方面，不存在重大遗漏。 （二）内部控制评价工作依据及内部控制缺陷认定标准 公司依据企业内部控制规范体系及遵循基本规范及评价指引的要求，组织开 展内部控制评价工作。 公司董事会根据企业内部控制规范体系对重大缺陷、重要缺陷和一 ...

重庆登康口腔护理用品股份有限公司 2024 年度 非经营性资金占用及其他关联资金往来的 专项说明 | 索引 | 页码 | | --- | --- | | 专项说明 | 1-2 | | 非经营性资金占用及其他关联资金往来情况汇总表 | 3 | 关于重庆登康口腔护理用品股份有限公司 1 2024 年度非经营性资金占用及其他关联资金往来的专项说明 XYZH/2025CDAA7B0165 重庆登康口腔护理用品股份有限公司 重庆登康口腔护理用品股份有限公司全体股东： 我们按照中国注册会计师审计准则审计了重庆登康口腔护理用品股份有限公司（以 下简称登康口腔公司）2024 年度财务报表，包括 2024 年 12 月 31 日的合并及母公司资 产负债表、2024 年度的合并及母公司利润表、合并及母公司现金流量表、合并及母公司 股 东 权 益 变 动 表 以 及 相 关 财 务 报 表 附 注 ， 并 于 2025 年 4 月 18 日 出 具 了 XYZH/2025CDAA7B0159 号无保留意见的审计报告。 根据中国证券监督管理委员会《上市公司监管指引第 8 号——上市公司资金往来、 对外担保的监管要求》（证监会公告[2 ...

重庆登康口腔护理用品股份有限公司 2024 年度 审计报告 | 索引 | | 页码 | | --- | --- | --- | | 审计报告 | | 1-5 | | 公司财务报表 | | | | — | 合并资产负债表 | 1-2 | | — | 母公司资产负债表 | 3-4 | | — | 合并利润表 | 5 | | — | 母公司利润表 | 6 | | — | 合并现金流量表 | 7 | | — | 母公司现金流量表 | 8 | | — | 合并股东权益变动表 | 9-10 | | — | 母公司股东权益变动表 | 11-12 | | — | 财务报表附注 | 13-84 | 审计报告 XYZH/2025CDAA7B0159 重庆登康口腔护理用品股份有限公司 重庆登康口腔护理用品股份有限公司全体股东： 一、 审计意见 我们审计了重庆登康口腔护理用品股份有限公司（以下简称登康口腔公司）财务报 表，包括 2024 年 12 月 31 日的合并及母公司资产负债表，2024 年度的合并及母公司利 润表、合并及母公司现金流量表、合并及母公司股东权益变动表，以及相关财务报表附 注。 我们认为，后附的财务报表在所有重大 ...